CBD shows promise for some children with epilepsy, but effectiveness varies

This Australian study followed 103 children with epilepsy over one year as they received purified cannabidiol (CBD), a non-psychoactive component of cannabis. The research provides important real-world data on whether CBD can help young epilepsy patients, particularly those with drug-resistant forms that don't respond well to traditional medications. Among children who continued the treatment, the results were encouraging: 40% showed substantial improvement in seizure control, with reductions in seizure frequency, emergency hospital visits, and the need for other anti-epilepsy medications.

However, the study also revealed significant challenges with CBD treatment for pediatric epilepsy. Nearly half of the participants (46%) discontinued treatment before the year ended, primarily because the drug didn't work for them or caused side effects. Of those who completed the study, 31% experienced adverse events, though most were mild to moderate. These findings highlight that while CBD can provide meaningful benefits for some children with epilepsy, individual responses vary dramatically, and the high discontinuation rate suggests clinicians need better tools to predict which patients will actually benefit before starting treatment.

The results underscore both the promise and the limitations of cannabidiol as a therapeutic option for pediatric epilepsy. For families facing drug-resistant epilepsy in children, this research offers genuine hope—particularly the documented reductions in seizures and emergency hospitalizations among responders. Yet the study's authors emphasize that more research is urgently needed to identify which children are most likely to respond to CBD and why others don't benefit, ensuring that future treatment can be better targeted and more effective across diverse patient populations.